ATLANTA -- With an "oral biologic" drug now on the horizon, clinicians are beginning to think again about the pluses and minuses of injectable drugs for rheumatoid arthritis and the most appropriate ways to treat patients in the real world.
In this exclusive InDepth video report from the American College of Rheumatology meeting, Roy Fleischmann, MD, of the University of Texas Southwestern Medical Center in Dallas, shared his perspective on these issues with MedPage Today senior editor John Gever.
One of the RA community's most prominent clinician-researchers, Fleischmann has led many of the clinical trials for the current generation of biologic drugs for RA. At this year's ACR meeting, he reported the first phase III data for tasocitinib, the much-anticipated oral agent that suppresses cytokine release.
http://www.medpagetoday.com/MeetingCoverage/ACR/23269
Copyright ArthritisInsight.com